Investment analysts at Piper Jaffray Cos. started coverage on shares of Astrazeneca PLC (NYSE:AZN) in a report issued on Friday. The brokerage set an “overweight” rating on the stock.
Several other equities analysts have also issued reports on AZN. BNP Paribas lowered shares of Astrazeneca PLC from an “outperform” rating to a “neutral” rating in a report on Tuesday, September 13th. Jefferies Group raised shares of Astrazeneca PLC from a “hold” rating to a “buy” rating in a report on Monday, September 12th. Vetr raised shares of Astrazeneca PLC from a “buy” rating to a “strong-buy” rating and set a $36.15 price objective on the stock in a report on Monday, September 12th. Berenberg Bank reissued a “buy” rating on shares of Astrazeneca PLC in a report on Sunday, September 11th. Finally, Deutsche Bank AG reissued a “buy” rating on shares of Astrazeneca PLC in a report on Thursday, September 8th. Two equities research analysts have rated the stock with a sell rating, eight have issued a hold rating, eleven have assigned a buy rating and three have assigned a strong buy rating to the company’s stock. Astrazeneca PLC presently has a consensus rating of “Buy” and an average price target of $37.49.
Shares of Astrazeneca PLC (NYSE:AZN) opened at 33.55 on Friday. Astrazeneca PLC has a 52 week low of $26.97 and a 52 week high of $35.04. The stock has a market capitalization of $84.88 billion, a price-to-earnings ratio of 38.34 and a beta of 0.77. The firm’s 50-day moving average is $33.45 and its 200-day moving average is $30.55.
Astrazeneca PLC (NYSE:AZN) last issued its earnings results on Thursday, July 28th. The company reported $0.83 EPS for the quarter, topping the Zacks’ consensus estimate of $0.76 by $0.07. The business had revenue of $5.60 billion for the quarter, compared to analyst estimates of $5.56 billion. Astrazeneca PLC had a net margin of 9.23% and a return on equity of 28.02%. The company’s quarterly revenue was down 4.0% compared to the same quarter last year. During the same period last year, the company posted $1.21 earnings per share. Analysts forecast that Astrazeneca PLC will post $2.97 earnings per share for the current fiscal year.
The company also recently disclosed a dividend, which was paid on Monday, September 12th. Shareholders of record on Friday, August 12th were issued a $0.44 dividend. The ex-dividend date was Wednesday, August 10th. Astrazeneca PLC’s payout ratio is 78.29%.
A number of hedge funds and other institutional investors have recently added to or reduced their stakes in AZN. JPMorgan Chase & Co. boosted its position in Astrazeneca PLC by 0.3% in the first quarter. JPMorgan Chase & Co. now owns 2,325,462 shares of the company’s stock worth $65,485,000 after buying an additional 6,027 shares during the last quarter. Integrated Investment Consultants LLC boosted its stake in Astrazeneca PLC by 6.1% in the second quarter. Integrated Investment Consultants LLC now owns 4,756 shares of the company’s stock worth $144,000 after buying an additional 275 shares in the last quarter. Ladenburg Thalmann Financial Services Inc. boosted its stake in Astrazeneca PLC by 3.1% in the first quarter. Ladenburg Thalmann Financial Services Inc. now owns 34,217 shares of the company’s stock worth $964,000 after buying an additional 1,027 shares in the last quarter. Fisher Asset Management LLC boosted its stake in Astrazeneca PLC by 45.2% in the second quarter. Fisher Asset Management LLC now owns 338,979 shares of the company’s stock worth $10,159,000 after buying an additional 105,570 shares in the last quarter. Finally, Teachers Advisors Inc. boosted its stake in Astrazeneca PLC by 595.6% in the first quarter. Teachers Advisors Inc. now owns 510,989 shares of the company’s stock worth $14,389,000 after buying an additional 437,531 shares in the last quarter. 11.39% of the stock is owned by institutional investors.
Astrazeneca PLC Company Profile
AstraZeneca PLC (AstraZeneca) is a biopharmaceutical company. The Company focuses on the discovery, development and commercialization of prescription medicines, primarily for the treatment of diseases in various therapy areas, including respiratory, inflammation, autoimmune disease (RIA), cardiovascular and metabolic disease (CVMD) and oncology, as well as in infection, neuroscience and gastrointestinal areas.
Receive News & Ratings for Astrazeneca PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Astrazeneca PLC and related companies with MarketBeat.com's FREE daily email newsletter.